



## Tumor Microenvironment Targeted Nanotherapy

Guest Editors:

### **Dr. Chaoyong Liu**

College of Life Science and  
Technology, Beijing University of  
Chemical Technology, Beijing  
100029, China

### **Dr. Haihua Xiao**

Key Laboratory of Polymer  
Physics and Chemistry, Institute  
of Chemistry, Chinese Academy  
of Sciences, Beijing 100190,  
China

Deadline for manuscript  
submissions:

**closed (20 April 2023)**

### **Message from the Guest Editors**

Recent findings suggest that the cellular and extracellular materials surrounding cancerous cells in an atypical tumor microenvironment (TME) play a pivotal role in tumor initiation and progression processes. The TME comprises an intricate system involving diverse cell types, including endothelial cells, pericytes, smooth muscle cells, fibroblasts, various inflammatory cells, dendritic cells, and cancer stem cells (CSCs). TME-forming cells dynamically interact with cancerous cells through various signaling mechanisms and pathways. Present-day researchers thus have a particular interest in exploiting these relationships to develop nanotherapeutics. Nanoparticles' benefits include their ability to passively target through the EPR effect and capacity to be easily modified with a variety of moieties for active targeting. Moreover, they can utilize the altered tumor environment to promote drug accumulation at tumor sites and modulate the tumor microenvironment by carrying drugs.

This Special Issue welcomes both reviews and original articles shedding light on nanotherapeutics targeting or regulating the tumor microenvironment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)